RBC Capital Reiterates Their Hold Rating on Depomed

By Carrie Williams

In a report issued on July 14, Randall Stanicky from RBC Capital reiterated a Hold rating on Depomed (NASDAQ: DEPO), with a price target of $13. The company’s shares closed on Friday at $10.80, close to its 52-week high of $27.02.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -7.7% and a 36.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Currently, the analyst consensus on Depomed is Hold and the average price target is $11.50, representing a 6.5% upside.

In a report issued on July 14, Piper Jaffray also reiterated a Hold rating on the stock with a $10 price target.

The company has a one year high of $27.02 and a one year low of $9.38. Currently, Depomed has an average volume of 1.51M.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. Last month, Thadd Vargas, the SVP BD of DEPO sold 202,387 shares for a total of $1,929,615.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Depomed, Inc. is a pharmaceutical company, which manufactures and distributes pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Newark, CA.